Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
Relay Therapeutics to report interim data for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer on Sept. 9, 2024, at 8am ET.
Reference News
Relay Therapeutics to report interim data for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer on September 9, 2024, at 8am ET. RLY-2608 is an allosteric, pan-mutant, isoform-selective PI3Kα inhibitor designed to overcome limitations of traditional orthosteric inhibitors.
RLY-2608, a PI3Kα inhibitor, showed 9.2-month median PFS in heavily pre-treated HR+/HER2- metastatic breast cancer patients, with 33% ORR and favorable tolerability. Plans for a 2L pivotal study in 2025 and triplet combinations with ribociclib and atirmociclib are underway.
Relay Therapeutics to report interim RLY-2608 data on September 9, 2024, focusing on 600mg BID + fulvestrant in CDK4/6-experienced, PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients from the ReDiscover trial. A conference call and webcast will discuss results and next steps, accessible via the company's website.
Relay Therapeutics' experimental breast cancer drug, RLY-2608, delayed tumor growth by 9 months in a trial, shrinking tumors in 75% of participants. The drug, targeting PI3Ka mutations, showed potential to replace existing treatments with less toxicity, prompting Relay to plan a pivotal trial for 2024. The study enrolled 118 patients with PI3Ka-mutated, HR-positive, HER2-negative breast cancer.
Relay Therapeutics to report interim data for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer on Sept. 9, 2024, at 8am ET.